Total Price: $0.00
Contact Information
Recombinant Human LR3-IGF-1 Protein (MG)(Active)
SKU: PKSH032712-50
Recombinant Human LR3-IGF-1 Protein (MG)(Active)
| SKU # | PKSH032712 |
| Expression Host | E.coli |
Description
| Synonyms | IBP1, IGF-I, IGF1, Insulin-Like Growth Factor I, MGF, Mechano Growth Factor, Somatomedin-C |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Gly49-Ala118 |
| Accession | P05019 |
| Calculated Molecular Weight | 9.1 kDa |
| Observed Molecular Weight | 11 kDa |
| Tag | None |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM NaAc-HAc, 4% Mannitol, pH 4.5. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Insulin-like growth factor I (IGF1) belongs to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGFs are generated by proteolytic processing of inactive precursor proteins; which contains the N- and C-terminal propeptide regions. Mature human IGF-I consisting of 70 amino acids has 94% identity with mouse IGF-I and exhibits cross-species activity. IGF-1 binds IGF-IR; IGF-IIR; and the insulin receptor and plays a key role in cell cycle progression; cell proliferation and tumor progression. IGF-1 expression is regulated by growth hormone. R3 IGF-1 is an 83 amino acid analog of IGF-1 comprising the complete human IGF-1 sequence with the substitution of an Arg (R) for the Glu(E) at position three; hence R3; and a 13 amino acid extension peptide at the N terminus. R3 IGF-1 has been produced with the purpose of increasing biological activity. R3 IGF-1 is significantly more potent than human IGF-I in vitro.